Company
i2O Therapeutics
GLP-1 Combinations for Obesity & Cardio-Renal-Metabolic Diseases
Also known as i2o Therapeutics, Inc
- Status
- Operatingas of 2026-09-17
- Legal name
- i2o Therapeutics, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Pipeline Assets Include: 2 Long-Acting GLP-1 RAs, 2 Long-Acting Amylin DACRAs, Long-Acting PYY RA & Long-Acting Glucagon RA
Funding snapshot
- Total raised
- $43.9MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $3.5M2023-09-18
Funding rounds
- Round, 2023
- $3.5M2023-09-18, SEC form D sold, 7 investors
- Round, 2022
- $33.5M2022-07-18, SEC form D sold, 17 investors
- Round, 2021
- $2.3M2021-10-01, SEC form D sold, 7 investors
- Round, 2020
- $600K2020-11-16, SEC form D sold, 2 investors
- Round, 2020
- $3.2M2020-03-13, SEC form D sold, 2 investors
- Round, 2019
- $800K2019-06-27, SEC form D sold, 2 investors
Loading relationship preview